Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Muntzing J, Shukla SK, Chu TM, Pharmacoclinical study of oral estramustine phosphate (Estracyt) in advanced carcinoma of the prostate. Invest Urol 1974;12:65-8
   PubMedGoogle Scholar
• Soloway MS, deKernion JB, Gibbons RP, Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J Urol 1981;125:664-7
   PubMed Web of Science ®Google Scholar
• Belotti D, Vergani V, Drudis T, The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Nakano M, Nicolaou KC, Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci USA 2002;99:10855-60
   PubMed Web of Science ®Google Scholar
• Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res 2012;72:4611-15
   PubMed Web of Science ®Google Scholar
• Poirier TI. Mitoxantrone. Drug Intell Clin Pharm 1986;20:97-105
   PubMedGoogle Scholar
• Tannock IF, Osoba D, Stockler MR, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64
   PubMed Web of Science ®Google Scholar
• Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003;170:1709-16
   PubMed Web of Science ®Google Scholar
• Tannock IF, de WR, Berry WR, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20
   PubMed Web of Science ®Google Scholar
• Serpa NA, Tobias-Machado M, Kaliks R, Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 randomized clinical trials. Clin Genitourin Cancer 2011;9:115-23
   PubMed Web of Science ®Google Scholar
• Scher HI, Jia X, Chi K, Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011;29:2191-8
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Carducci M, Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30:1534-40
   PubMed Web of Science ®Google Scholar
• Meulenbeld HJ, van Werkhoven ED, Coenen JL, Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). Eur J Cancer 2012;48:2993-3000
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Creel P, Turnbull J, A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270-6
   PubMed Web of Science ®Google Scholar
• Quinn DI, Tangen CM, Hussain M, SWOG S0421: Phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 2012;30(Suppl); abstract 4511
   Google Scholar
• Higano C, Saad F, Somer B, A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract LBA150]. Genitourinary Cancers Symposium; 26-28 Feb 2009; Orlando, FL
   Google Scholar
• Small E, Demkow T, Gerritsen R, A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract 7]. Genitourinary Cancers Symposium; 26-28 Feb 2009; Orlando, FL
   Google Scholar
• Nelson JB, Fizazi K, Miller K, Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012;118:5709-18
   PubMed Web of Science ®Google Scholar
• Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap® (aflibercept). Sanofi, Tarrytown, NY; 2012. Available from: http://en.sanofi.com/Images/30138_20120405_ZALTRAP_BLA_VENICE_en.pdf [Last accessed 11 December 2012]
   Google Scholar
• Lenalidomide Plus Docetaxel: phase III Results Fall Short. OncLive, Plainsboro, NJ; 2012. Available from: http://www.onclive.com/publications/oncology-live/2012/january-2012/Lenalidomide-Plus-Docetaxel-Phase-III-Results-Fall-Short [Last accessed 11 December 2012]
   Google Scholar
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer (READY). US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT00744497 [Last accessed 12 December 2012]
   Google Scholar
• Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY). US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01188187 [Last accessed 12 December 2012]
   Google Scholar
• Araujo JC, Mathew P, Armstrong AJ, Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 2012;118:63-71
   PubMed Web of Science ®Google Scholar
• Chi KN, Hotte SJ, Yu EY, Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:4247-54
   PubMed Web of Science ®Google Scholar
• Tamaskar I, Mekhail T, Dreicer R, Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease. Invest New Drugs 2008;26:553-9
   PubMed Web of Science ®Google Scholar
• Facchini G, Caraglia M, Morabito A, Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial. Cancer Biol Ther 2010;10:543-8
   PubMed Web of Science ®Google Scholar
• Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998;16:3674-90
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
   PubMed Web of Science ®Google Scholar
• Heck MM, Hoppner M, Horn T, Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients. Urologe A 2012; published online; doi:10.1007/s00120-012-2804-y
   Google Scholar
• De Velasco G, Aparicio LA, Esteban E, Cabazitaxel in patients with advanced CRPC after docetaxel failure: results of expanded program access (EAP) in Spain: Safety and efficacy [abstract]. J Clin Oncol 2012;30(Suppl):abstract e15149
   Google Scholar
• Bracarda S, Di Lorenzo G, Gasparro D, Updated safety result of a large Italian early access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) therapy [abstract]. J Clin Oncol 2012;30(Suppl):abstract e15185
   Google Scholar
• Roth BJ, Yeap BY, Wilding G, Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72:2457-60
   PubMed Web of Science ®Google Scholar
• Hudes GR, Nathan F, Khater C, Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15:3156-63
   PubMed Web of Science ®Google Scholar
• Smith DC, Esper P, Strawderman M, Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999;17:1664-71
   PubMed Web of Science ®Google Scholar
• Smith DC, Chay CH, Dunn RL, Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 2003;98:269-76
   PubMed Web of Science ®Google Scholar
• Berry W, Friedland D, Fleagle J, A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. Clin Genitourin Cancer 2006;5:131-7
   PubMed Web of Science ®Google Scholar
• Mackler NJ, Pienta KJ, Dunn RL, Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. Clin Genitourin Cancer 2007;5:318-22
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Elfiky A, Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer 2008;113:3137-45
   PubMed Web of Science ®Google Scholar
• Sanfilippo NJ, Taneja SS, Chachoua A, Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol 2008;26:2973-8
   PubMed Web of Science ®Google Scholar
• Sella A, Yarom N, Zisman A, Kovel S. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer. Oncology 2009;76:442-6
   PubMed Web of Science ®Google Scholar
• Sewak S, Kosmider S, Ganju V, Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting. Intern Med J 2010;40:201-8
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Chen YH, Stein M, A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med 2010;8:20
   PubMedGoogle Scholar
• Beer TM, Ryan C, Alumkal J, A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs 2010;21:433-8
   PubMed Web of Science ®Google Scholar
• Smith DC, Tangen CM, Van Veldhuizen PJJ, Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: southwest Oncology Group S0032. Urology 2011;77:1172-6
   PubMed Web of Science ®Google Scholar
• Jeske S, Tagawa ST, Olowokure O, Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. Urol Oncol 2011;29:676-81
   PubMed Web of Science ®Google Scholar
• Desai N, Trieu V, Yao Z, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24
   PubMed Web of Science ®Google Scholar
• Shepard DR, Dreicer R, Garcia J, Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol 2009;181:1672-7
   PubMedGoogle Scholar
• Kolevska T, Ryan CJ, Huey V, Phase II trial of nab-paclitaxel as first-line therapy of hormone refractory metastatic prostate cancer (HRPC) [abstr 5152]. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Phase I Abraxane Weekly and Three Weekly Schedule With Vandetanib. US National Institute of Health, Bethesda, MD; 2013. Available from: http://clinicaltrial.gov/ct2/show/NCT00667147 [Last accessed 21 January 2013]
   Google Scholar
• Shionoya M, Jimbo T, Kitagawa M, DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 2003;94:459-66
   PubMed Web of Science ®Google Scholar
• Baas P, Szczesna A, Albert I, Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J Thorac Oncol 2008;3:745-50
   PubMed Web of Science ®Google Scholar
• Saif MW, Sarantopoulos J, Patnaik A, Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;68:1565-73
   PubMed Web of Science ®Google Scholar
• Tesetaxel in chemotherapy-naive patients with progressive, castration-resistant prostate cancer. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01296243 [Last accessed 12 December 2012]
   Google Scholar
• Daliani DD, Assikis V, Tu SM, Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer 2003;97:561-7
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L, Balog A, Su DS, The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate Cancer Prostatic Dis 1999;2:41-52
   PubMed Web of Science ®Google Scholar
• Lee FY, Borzilleri R, Fairchild CR, BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37
   PubMed Web of Science ®Google Scholar
• Chou TC, O'Connor OA, Tong WP, The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci USA 2001;98:8113-18
   PubMed Web of Science ®Google Scholar
• Dorff TB, Gross ME. The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist 2011;16:1349-58
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Gomez HL, Li RK, Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010;122:409-18
   PubMed Web of Science ®Google Scholar
• Sparano JA, Vrdoljak E, Rixe O, Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010;28:3256-63
   PubMed Web of Science ®Google Scholar
• Roche H, Conte P, Perez EA, Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat 2011;125:755-65
   PubMed Web of Science ®Google Scholar
• Jassem J, Fein L, Karwal M, Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast 2012;21:89-94
   PubMed Web of Science ®Google Scholar
• Withdrawal of IXEMPRA, (ixabepilone) EMEA/H/C/000930. European Medicines Agency, London, UK, 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/01/WC500062430.pdf [Last accessed 12 December 2012]
   Google Scholar
• Smaletz O, Galsky M, Scher HI, Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol 2003;14:1518-24
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Ryan CJ, Weinberg VK, Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol 2009;27:2772-8
   PubMed Web of Science ®Google Scholar
• Galsky MD, Small EJ, Oh WK, Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005;23:1439-46
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Weinberg VK, Kelly WK, Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556-63
   PubMed Web of Science ®Google Scholar
• Liu G, Chen YH, Dipaola R, Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 2012;10:99-105
   PubMed Web of Science ®Google Scholar
• Layton JL, Plette AM, Renzulli JF, The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: a phase I/II clinical trial. [abstract]. J Clin Oncol 2012;30(Suppl 5; abstract 158
   Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59
   PubMed Web of Science ®Google Scholar
• Hussain A, DiPaola RS, Baron AD, Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009;20:492-7
   PubMed Web of Science ®Google Scholar
• Chi KN, Beardsley E, Eigl BJ, A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: canadian Urologic Oncology Group study P07a. Ann Oncol 2012;23:53-8
   PubMed Web of Science ®Google Scholar
• Beer TM, Higano CS, Saleh M, Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007;25:565-70
   PubMed Web of Science ®Google Scholar
• Beer TM, Smith DC, Hussain A, Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer 2012;107:808-13
   PubMed Web of Science ®Google Scholar
• Roberts K. Cytoplasmic microtubules and their functions. Prog Biophys Mol Biol 1974;28:371-420
   PubMedGoogle Scholar
• Mayer TU, Kapoor TM, Haggarty SJ, Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4
   PubMed Web of Science ®Google Scholar
• Kapitein LC, Peterman EJ, Kwok BH, The bipolar mitotic kinesin Eg5 moves on both microtubules that it crosslinks. Nature 2005;435:114-18
   PubMed Web of Science ®Google Scholar
• Sarli V, Giannis A. Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 2008;14:7583-7
   PubMed Web of Science ®Google Scholar
• Vijapurkar U, Wang W, Herbst R. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways. Cancer Res 2007;67:237-45
   PubMed Web of Science ®Google Scholar
• Tao W, South VJ, Diehl RE, An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis. Mol Cell Biol 2007;27:689-98
   PubMed Web of Science ®Google Scholar
• Liu M, Aneja R, Liu C, Inhibition of the mitotic kinesin Eg5 up-regulates Hsp70 through the phosphatidylinositol 3-kinase/Akt pathway in multiple myeloma cells. J Biol Chem 2006;281:18090-7
   PubMed Web of Science ®Google Scholar
• Chin GM, Herbst R. Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint. Mol Cancer Ther 2006;5:2580-91
   Google Scholar
• Lad L, Luo L, Carson JD, Mechanism of inhibition of human KSP by ispinesib. Biochemistry 2008;47:3576-85
   PubMed Web of Science ®Google Scholar
• Blagden SP, Molife LR, Seebaran A, A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer 2008;98:894-9
   PubMed Web of Science ®Google Scholar
• Burris HA III, Jones SF, Williams DD, A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 2011;29:467-72
   PubMed Web of Science ®Google Scholar
• Chu QS, Holen KD, Rowinsky EK, Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV Q 21 days [abstract 2078]. J Clin Oncol 2004;22(Suppl):14S
   Google Scholar
• Heath EI, Alousi A, Eder JP, A phase I dose escalation trial of ispinesib (SB-715992) administered days 1-3 of a 21-day cycle in patients with advanced solid tumors [abstrac 2026]. J Clin Oncol 2006;24(Suppl):18S
   Google Scholar
• Beer TM, Goldman B, Synold TW, Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer 2008;6:103-9
   PubMed Web of Science ®Google Scholar
• Xing ND, Ding ST, Saito R, A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor. Asian J Androl 2011;13:236-41
   PubMed Web of Science ®Google Scholar
• Holen KD, Belani CP, Wilding G, A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol 2011;67:447-54
   PubMed Web of Science ®Google Scholar
• Holen K, Dipaola R, Liu G, A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs 2011; published online; doi:10.1007/s10637-011-9653-1
   Google Scholar
• Esaki T, Seto T, Ariyama H, Phase I study to assess the safety, tolerability and pharmacokinetics of AZD4877 in Japanese patients with solid tumors. Arch Drug Inf 2011;4:23-31
   PubMedGoogle Scholar
• Infante JR, Kurzrock R, Spratlin J, A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;69:165-72
   PubMed Web of Science ®Google Scholar
• Stephenson JJ, Lewis N, Martin JC, Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies [abstract]. J Clin Oncol 2008;26(Suppl); abstract 2516
   Google Scholar
• Goncalves PH, Sausville EA, Edelman MJ, A phase I study of ARRY-520 in solid tumors [abstract 2570]. J Clin Oncol 2010;28(Suppl):15s
   Google Scholar
• Nakai R, Iida S, Takahashi T, K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. Cancer Res 2009;69:3901-9
   PubMed Web of Science ®Google Scholar
• Wiltshire C, Singh BL, Stockley J, Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. Mol Cancer Ther 2010;9:1730-9
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003;4:842-54
   PubMed Web of Science ®Google Scholar
• Dar AA, Goff LW, Majid S, Aurora kinase inhibitors–rising stars in cancer therapeutics? Mol Cancer Ther 2010;9:268-78
   PubMed Web of Science ®Google Scholar
• Hirota T, Kunitoku N, Sasayama T, Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-98
   PubMed Web of Science ®Google Scholar
• Marumoto T, Hirota T, Morisaki T, Roles of aurora-A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 2002;7:1173-82
   PubMed Web of Science ®Google Scholar
• Marumoto T, Honda S, Hara T, Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-95
   PubMed Web of Science ®Google Scholar
• Berdnik D, Knoblich JA. Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Curr Biol 2002;12:640-7
   PubMed Web of Science ®Google Scholar
• Terada Y, Tatsuka M, Suzuki F, AIM-1: a mammalian midbody-associated protein required for cytokinesis. EMBO J 1998;17:667-76
   PubMed Web of Science ®Google Scholar
• Slattery SD, Mancini MA, Brinkley BR, Hall RM. Aurora-C kinase supports mitotic progression in the absence of Aurora-B. Cell Cycle 2009;8:2984-94
   PubMed Web of Science ®Google Scholar
• Khan J, Ezan F, Cremet JY, Overexpression of active Aurora-C kinase results in cell transformation and tumour formation. PLoS ONE 2011;6:e26512
   PubMed Web of Science ®Google Scholar
• Chieffi P, Cozzolino L, Kisslinger A, Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006;66:326-33
   PubMed Web of Science ®Google Scholar
• Beltran H, Rickman DS, Park K, Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487-95
   PubMed Web of Science ®Google Scholar
• Mosquera JM, Beltran H, Park K, Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 2013;15:1-10
   PubMed Web of Science ®Google Scholar
• Jeet V, Russell PJ, Verma ND, Khatri A. Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer. Curr Cancer Drug Targets 2011; published online; doi:EPub-Abstract-CCDT-188 [pii]
   Web of Science ®Google Scholar
• Shu SK, Liu Q, Coppola D, Cheng JQ. Phosphorylation and activation of androgen receptor by Aurora-A. J Biol Chem 2010;285:33045-53
   PubMed Web of Science ®Google Scholar
• Jeong NY, Yoon YG, Rho JH, The novel resveratrol analog HS-1793-induced polyploid LNCaP prostate cancer cells are vulnerable to downregulation of Bcl-xL. Int J Oncol 2011;38:1597-604
   PubMed Web of Science ®Google Scholar
• Moretti L, Niermann K, Schleicher S, MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Int J Radiat Oncol Biol Phys 2011;80:1189-97
   PubMed Web of Science ®Google Scholar
• Fancelli D, Moll J, Varasi M, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J Med Chem 2006;49:7247-51
   PubMed Web of Science ®Google Scholar
• Carpinelli P, Ceruti R, Giorgini ML, PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68
   PubMed Web of Science ®Google Scholar
• Steeghs N, Eskens FA, Gelderblom H, Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009;27:5094-101
   PubMed Web of Science ®Google Scholar
• Cohen RB, Jones SF, Aggarwal C, A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009;15:6694-701
   PubMed Web of Science ®Google Scholar
• Meulenbeld HJ, Bleuse JP, Vinci EM, Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int 2012; published online; doi:10.1111/j.1464-410X.2012.11404.x
   PubMed Web of Science ®Google Scholar
• Sells T, Ecsedy JA, Stroud S, MLN8237: an orally active small molecule inhibitor of aurora A kinase in phase I clinical trials [abstract]. Proc Am Assoc Cancer Res (AACR) 2008;49;abstract 2997
   Google Scholar
• Manfredi MG, Ecsedy JA, Chakravarty A, Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Clin Cancer Res 2011;17:7614-24
   PubMed Web of Science ®Google Scholar
• Maris JM, Morton CL, Gorlick R, Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34
   PubMed Web of Science ®Google Scholar
• Dees EC, Cohen RB, von MM, Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012;18:4775-84
   PubMed Web of Science ®Google Scholar
• A Phase 1 study of MLN8237 in patients with advanced solid tumors including castration-resistant prostate cancer receiving a standard docetaxel regimen. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01094288 [Last accessed 12 December 2012]
   Google Scholar
• Mortlock AA, Foote KM, Heron NM, Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. J Med Chem 2007;50:2213-24
   PubMed Web of Science ®Google Scholar
• Wilkinson RW, Odedra R, Heaton SP, AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007;13:3682-8
   PubMed Web of Science ®Google Scholar
• Niermann KJ, Moretti L, Giacalone NJ, Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition. Radiat Res 2011;175:444-51
   PubMed Web of Science ®Google Scholar
• Boss DS, Witteveen PO, van der Sar J, Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 2011;22:431-7
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Carvajal RD, Midgley R, Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 2012; published online; doi:10.1007/s10637-012-9825-7
   Google Scholar
• Sawyers CL. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 2002;1:413-15
   PubMed Web of Science ®Google Scholar
• Fletcher GC, Brokx RD, Denny TA, ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther 2011;10:126-37
   PubMed Web of Science ®Google Scholar
• Diamond JR, Bastos BR, Hansen RJ, Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2011;17:849-60
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Lee J, Lasonde B, ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer 2012; published online; doi:S0959-8049(12)00603-X [pii];10.1016/j.ejca.2012.07.020
   PubMed Web of Science ®Google Scholar
• Study of ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01719744 [Last accessed 12 December 2012]
   Google Scholar
• A Phase II study of the aurora and angiogenic kinase inhibitor ENMD-2076 in previously treated locally advanced and metastatic triple-negative breast cancer. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01639248 [Last accessed 12 December 2012]
   Google Scholar
• Harrington EA, Bebbington D, Moore J, VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7
   PubMed Web of Science ®Google Scholar
• Traynor AM, Hewitt M, Liu G, Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67:305-14
   PubMed Web of Science ®Google Scholar
• Howard S, Berdini V, Boulstridge JA, Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88
   PubMed Web of Science ®Google Scholar
• Dawson MA, Curry JE, Barber K, AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. Br J Haematol 2010;150:46-57
   PubMed Web of Science ®Google Scholar
• Jani JP, Arcari J, Bernardo V, PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy. Mol Cancer Ther 2010;9:883-94
   PubMed Web of Science ®Google Scholar
• Gürtler U, Tontsch-Grunt U, Jarvis M, Effect of BI 811283, a novel inhibitor of Aurora B kinase, on tumor senescence and apoptosis [abstract]. J Clin Oncol 2010;28(Suppl):abstract e13632
   Google Scholar
• VanderPorten EC, Taverna P, Hogan JN, The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther 2009;8:930-9
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Plummer R, Molife LR, A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 2011; published online; doi:mdr451 [pii];10.1093/annonc/mdr451
   Web of Science ®Google Scholar
• Mross KB, Scheulen ME, Frost A, A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered every three weeks in patients with advanced solid tumors [abstract 3011]. J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar
• Scheulen ME, Mross KB, Richly H, A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered days 1 and 15, every four weeks in patients with advanced solid tumors [abstract]. J Clin Oncol 2010;28(Suppl):abstract e13065
   Google Scholar
• Schoffski P, Jones SF, Dumez H, Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 2011;47:2256-64
   PubMed Web of Science ®Google Scholar
• Minton SE, LoRusso P, Lockhart AC, A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors [abstract]. J Clin Oncol 2010;28(Suppl):abstract e13026
   Google Scholar
• Robert F, Verschraegen C, Hurwitz H, A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients [abstract 2536]. J Clin Oncol 2009;27(Suppl):15s
   Google Scholar
• Xie H, Lee MH, Zhu F, Identification of an Aurora kinase inhibitor specific for the Aurora B isoform. Cancer Res 2012; published online; doi:0008-5472.CAN-12-2784 [pii];10.1158/0008-5472.CAN-12-2784
   Web of Science ®Google Scholar
• Payton M, Bush TL, Chung G, Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 2010;70:9846-54
   PubMed Web of Science ®Google Scholar
• Anderson K, Lai Z, McDonald OB, Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. Biochem J 2009;420:259-65
   PubMed Web of Science ®Google Scholar
• Carducci MA, Shaheen MF, Paller CJ, First-in-human study of AMG 900, an oral pan-Aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors. [abstract]. J Clin Oncol 2012;30(Suppl); abstract 3009
   PubMedGoogle Scholar
• Adams ND, Adams JL, Burgess JL, Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem 2010;53:3973-4001
   PubMed Web of Science ®Google Scholar
• Hardwicke MA, Oleykowski CA, Plant R, GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther 2009;8:1808-17
   PubMed Web of Science ®Google Scholar
• Aurora B/C kinase inhibitor GSK1070916A in treating patients with advanced solid tumors. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01118611 [Last accessed 12 December 2012]
   Google Scholar
• de CG, Manning G, Malumbres M. From Plk1 to Plk5: functional evolution of polo-like kinases. Cell Cycle 2011;10:2255-62
   PubMed Web of Science ®Google Scholar
• Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010;19:27-43
   PubMed Web of Science ®Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 2010;9:643-60
   PubMed Web of Science ®Google Scholar
• Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis–cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008;20:650-60
   PubMed Web of Science ®Google Scholar
• Liu XS, Song B, Liu X. The substrates of Plk1, beyond the functions in mitosis. Protein Cell 2010;1:999-1010
   PubMed Web of Science ®Google Scholar
• Weichert W, Schmidt M, Gekeler V, Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004;60:240-5
   PubMed Web of Science ®Google Scholar
• Deeraksa A, Pan J, Sha Y, Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis. Oncogene 2012; published online; doi:onc2012309 [pii];10.1038/onc.2012.309 [doi]
   PubMed Web of Science ®Google Scholar
• Takagi M, Honmura T, Watanabe S, In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs 2003;21:387-99
   PubMed Web of Science ®Google Scholar
• Garland LL, Taylor C, Pilkington DL, A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res 2006;12:5182-9
   PubMed Web of Science ®Google Scholar
• Patnaik A, Forero L, Goetz A, HMN-214, a novel oral antimicrotubular agent and inhibitor of pololike- and cyclin-dependent kinases: clinical, pharmacokinetic (PK) and pharmacodynamic (PD) relationships observed in a phase I trial of a daily x 5 schedule every 28 days [abstract]. J Clin Oncol 2003;22(Suppl); abstract 514
   Google Scholar
• Steegmaier M, Hoffmann M, Baum A, BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-22
   PubMed Web of Science ®Google Scholar
• Rudolph D, Steegmaier M, Hoffmann M, BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15:3094-102
   PubMed Web of Science ®Google Scholar
• Wissing MD, Rosmus N, Gonzalez M, Targeting prostate cancer through a combination of Polo-like kinase inhibitors and histone deacetylase inhibitors [abstract]. Proc Am Assoc Cancer Res (AACR) 2010;abstract 5414
   Google Scholar
• Mross K, Frost A, Steinbild S, Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:5511-17
   PubMed Web of Science ®Google Scholar
• Hofheinz RD, Al-Batran SE, Hochhaus A, An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 2010;16:4666-74
   PubMed Web of Science ®Google Scholar
• Pandha HS, Protheroe A, Wylie J, An open label phase II trial of BI 2536, a novel Plk1 inhibitor, in patients with metastatic hormone refractory prostate cancer (HRPC) [abstract]. J Clin Oncol 2008;26(Suppl); abstract 14547
   Google Scholar
• Schoffski P, Awada A, Dumez H, A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012;48:179-86
   PubMed Web of Science ®Google Scholar
• Dumez H, Gombos A, Schöffski P, Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors [abstract]. J Clin Oncol 2012;30(Suppl): abstract 3018^
   Google Scholar
• Stadler WM, Vaughn DJ, Sonpavde G, Phase II study of single-agent volasertib (BI 6727) for second-line treatment of urothelial cancer (UC) [abstract]. J Clin Oncol 2011;29(Suppl 7); abstract 253
   Web of Science ®Google Scholar
• Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01022853 [Last accessed 12 December 2012]
   Google Scholar
• BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01121406 [Last accessed 12 December 2012]
   Google Scholar
• An Open label phase i dose escalation trial of intravenous BI 6727 (Volasertib)in combination with oral BIBW 2992 (Afatinib) in patients with advanced solid tumours. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01206816 [Last accessed 12 December 2012]
   Google Scholar
• BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01348347 [Last accessed 12 December 2012]
   Google Scholar
• Gilmartin AG, Bleam MR, Richter MC, Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009;69:6969-77
   PubMed Web of Science ®Google Scholar
• Laquerre S, Sung C, Gilmartin A, A potent and selective Polo-like kinase 1 (Plk1) Inhibitor (GSK461364) induces cell cycle arrest and growth inhibition of cancer cell [abstract]. Proc Am Assoc Cancer Res (AACR) 2007;abstract 5389
   Google Scholar
• Olmos D, Barker D, Sharma R, Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2011;17:3420-30
   PubMed Web of Science ®Google Scholar
• Study of NMS-1286937 in adult patients with advanced/metastatic solid tumors. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01014429 [Last accessed 12 December 2012]
   Google Scholar
• Dose escalation study to determine safety, pharmacokinetics, and pharmacodynamics of intravenous TKM-080301. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01262235 [Last accessed 12 December 2012]
   Google Scholar
• Study of orally administered TAK-960 in patients with advanced nonhematologic malignancies. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01179399 Last accessed 12 December 2012]
   Google Scholar
• Beria I, Bossi RT, Brasca MG, NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Bioorg Med Chem Lett 2011;21:2969-74
   PubMed Web of Science ®Google Scholar
• Valsasina B, Beria I, Alli C, NMS-P937, an orally available, specific, small molecule Polo-Like Kinase 1 inhibitor with antitumor activity in solid and haematological malignancies. Mol Cancer Ther 2012; published online; doi:1535-7163.MCT-11-0765 [pii];10.1158/1535-7163.MCT-11-0765
   PubMed Web of Science ®Google Scholar
• Hikichi Y, Honda K, Hikami K, TAK-960, a novel, orally available, selective inhibitor of Polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther 2011; published online; doi:1535-7163.MCT-11-0762 [pii];10.1158/1535-7163.MCT-11-0762
   PubMed Web of Science ®Google Scholar
• Judge AD, Robbins M, Tavakoli I, Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009;119:661-73
   PubMed Web of Science ®Google Scholar
• Semple SC, Judge AD, Robbins M, Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1 [abstract]. Proc Am Assoc Cancer Res (AACR) 2011;71(Suppl 8); abstract 2829
   Google Scholar
• Gumireddy K, Reddy MV, Cosenza SC, ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005;7:275-86
   PubMed Web of Science ®Google Scholar
• Chapman CM, Sun X, Roschewski M, ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012;18:1979-91
   PubMed Web of Science ®Google Scholar
• Ma WW, Messersmith WA, Dy GK, Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res 2012;18:2048-55
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-29
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84
   PubMed Web of Science ®Google Scholar
• Qi W, Liu X, Cooke LS, AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer 2011; published online; doi:10.1002/ijc.26324 [doi]
   Web of Science ®Google Scholar
• Qi W, Cooke LS, Liu X, Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 2011;81:881-90
   PubMed Web of Science ®Google Scholar
• Feng B, Wang R, Chen LB. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 2012;317:184-91
   PubMed Web of Science ®Google Scholar
• Kachhap SK, Rosmus N, Collis SJ, Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS ONE 2010;5:e11208
   PubMed Web of Science ®Google Scholar
• Paller C, Wissing M, Kim E, Preclinical profile of AMG900 in combination with HDACIs in prostate cancer [abstract]. Proc Am Assoc Cancer Res (AACR) 2012;abstract 2049
   Google Scholar
• Marin-Aguilera M, Codony-Servat J, Kalko SG, Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 2012;11:329-39
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012;22:373-88
   PubMed Web of Science ®Google Scholar
• Madan RA, Pal SK, Sartor O, Dahut WL. Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res 2011;17:3892-902
   PubMed Web of Science ®Google Scholar
• Beer TM, Javle MM, Ryan CW, Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol 2007;59:581-7
   PubMed Web of Science ®Google Scholar
• Coleman RL, Duska LR, Ramirez PT, Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011;12:1109-17
   PubMed Web of Science ®Google Scholar
• Isambert N, Freyer G, Zanetta S, Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res 2012;18:1743-50
   PubMed Web of Science ®Google Scholar
• Demetri GD, Lo RP, MacPherson IR, Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15:6232-40
   PubMed Web of Science ®Google Scholar
• Eisenberger MA, Hardy-Bessard A, Mourey L, Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen [abstract]. J Clin Oncol 2012;30(Suppl):abstract TPS4692
   Google Scholar
• Study of Weekly Cabazitaxel for Advanced Prostate Cancer. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01518283 [Last accessed 21 December 2012]
   Google Scholar
• A study looking at novel scheduling of cabazitaxel for patients with metastatic prostate cancer (ConCab). US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01541007 [Last accessed 21 December 2012]
   Google Scholar
• Second-line chemotherapy in castration resistant prostate cancer (ProstyII). US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01558219 [Last accessed 21 December 2012]
   Google Scholar
• Cabazitaxel plus prednisone with octreotide for Castration-Resistant Prostate Cancer (CRPC) previously treated with docetaxel. us national institute of health. Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01469338 [Last accessed 21 December 2012]
   Google Scholar
• Cabaresc NL. Stichting DUOS; Rotterdam, NL: 2012. Available from: http://www.stichtingduos.nl/studies/cabaresc-nl/ [ [Last accessed 21 December 2012]
   Google Scholar
• Cabazitaxel versus docetaxel both with prednisone in patients with metastatic castration resistant prostate cancer (FIRSTANA). US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01308567 [Last accessed 21 December 2012]
   Google Scholar
• Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY). US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01578655 [Last accessed 21 December 2012]
   Google Scholar
• The CATCH prostate cancer trial: cabazitaxel and tasquinimod in men with prostate cancer. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01513733 [Last accessed 21 December 2012]
   Google Scholar
• Cabazitaxel and abiraterone acetate in patients with metastatic castrate-resistant prostate cancer. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01511536 [Last accessed 21 December 2012]
   Google Scholar
• Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01335204 [Last accessed 21 December 2012]
   Google Scholar
• Cabazitaxel with or without carboplatin in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01505868 Last accessed 21 December 2012]
   Google Scholar
• De Souza PL, Mellado B, Pfister C, Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar
• Gerecitano JF, Stephenson JJ, Lewis NL, A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Invest New Drugs 2012; published online; doi:10.1007/s10637-012-9821-y [doi]
   PubMedGoogle Scholar
• Macarulla T, Cervantes A, Elez E, Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 2010;9:2844-52
   PubMed Web of Science ®Google Scholar
• Dees EC, Infante JR, Cohen RB, Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;67:945-54
   PubMed Web of Science ®Google Scholar
• Cervantes A, Elez E, Roda D, Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012;18:4764-74
   PubMed Web of Science ®Google Scholar
• Mosse YP, Lipsitz E, Fox E, Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of aurora kinase a: a children's oncology group phase I consortium study. Clin Cancer Res 2012;18:6058-64
   PubMed Web of Science ®Google Scholar
• Matulonis UA, Sharma S, Ghamande S, Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol 2012;127:63-9
   PubMed Web of Science ®Google Scholar
• Lee P, Alvarez RH, Melichar B, Phase I/II study of the investigational aurora A kinase (AAK) inhibitor MLN8237 (alisertib) in patients (pts) with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer (BrC), head/neck cancer (H&N), and gastroesophageal (GE) adenocarcinoma: Preliminary phase II results [abstract]. J Clin Oncol 2012;30(Suppl):abstract 3010
   Google Scholar
• Falchook GS, Goff BA, Kurzrock R, Phase I/II study of weekly paclitaxel with or without MLN8237 (alisertib), an investigational aurora A kinase inhibitor, in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (OC), or breast cancer (BrC): Phase I results [abstract]. J Clin Oncol 2012;30(Suppl):abstract 5021
   Google Scholar
• Frost A, Mross K, Steinbild S, Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol 2012;19:e28-35
   PubMed Web of Science ®Google Scholar
• Ellis PM, Chu QS, Leighl N, A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer 2012; published online; doi:S1525-7304(12)00080-0 [pii];10.1016/j.cllc.2012.04.003
   PubMed Web of Science ®Google Scholar
• Schoffski P, Blay JY, De GJ, Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010;46:2206-15
   PubMed Web of Science ®Google Scholar
• Sebastian M, Reck M, Waller CF, The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol 2010;5:1060-7
   PubMed Web of Science ®Google Scholar
• Mross K, Dittrich C, Aulitzky WE, A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012;107:280-6
   PubMed Web of Science ®Google Scholar
• BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours.US National Institute of Health. Bethesda, MD; 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01145885 [Last accessed 21 December 2012]
   Google Scholar
• Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT00969553 [Last accessed 21 December 2012]
   Google Scholar
• Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT00824408 [Last accessed 21 December 2012]
   Google Scholar
• Jimeno A, Li J, Messersmith WA, Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-10
   PubMed Web of Science ®Google Scholar
• Ohnuma T, Holland JF, Goel S, Final results of a phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors [abstract]. J Clin Oncol 2011;29(Suppl):abstract e13584
   Google Scholar
• Bowles DW, Diamond JR, Lam ET, Phase I study of oral rigosertib in patients with advanced solid tumors [abstract]. J Clin Oncol 2012;30(Suppl); abstract 3017
   Google Scholar
• Vainshtein JM, Ghalib MH, Kumar M, Phase I study of ON 01910.Na, a novel polo-like kinase 1 pathway modulator, administered as a weekly 24-hour continuous infusion in patients with advanced cancer [abstract]. J Clin Oncol 2008;26(Suppl); abstract 2515
   Google Scholar
• Ohnuma T, Cho SY, ROboz J, Phase I study of ON 01910.Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer [abstract 13137]. J Clin Oncol 2006;24(Suppl):18S
   Google Scholar
• Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01168011 [Last accessed 21 December 2012]
   Google Scholar
• Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients. US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT00856791 [Last accessed 21 December 2012]
   Google Scholar
• Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC). US National Institute of Health, Bethesda, MD; 2012. Available from: http://clinicaltrial.gov/ct2/show/NCT01360853 [Last accessed 21 December 2012]
   Google Scholar